Danaher (NYSE:DHR) Raised to “Buy” at Wall Street Zen

Danaher (NYSE:DHR) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Monday, Wall Street Zen reports.

Several other equities analysts have also recently issued reports on the company. Weiss Ratings upgraded Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Stifel Nicolaus increased their price objective on Danaher from $220.00 to $260.00 and gave the stock a “buy” rating in a research report on Thursday, October 22nd. UBS Group reaffirmed a “buy” rating and set a $260.00 price objective on shares of Danaher in a research report on Thursday, October 22nd. Citigroup lifted their target price on Danaher from $230.00 to $270.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $240.00 target price on shares of Danaher in a report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $242.91.

Danaher Trading Down 0.4%

Shares of NYSE:DHR opened at $232.00 on Monday. Danaher has a 1-year low of $160.93 and a 1-year high of $242.80. The firm has a fifty day moving average price of $217.41 and a 200 day moving average price of $201.82.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, beating analysts’ consensus estimates of $1.92 by $0.19. The business had revenue of $6.55 billion during the quarter, compared to analyst estimates of $6.56 billion. During the same quarter in the prior year, the firm posted $1.89 earnings per share. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. On average, research analysts forecast that Danaher will post 8.59 EPS for the current fiscal year.

Hedge Funds Weigh In On Danaher

Hedge funds and other institutional investors have recently bought and sold shares of the company. Prime Capital Investment Advisors LLC raised its holdings in shares of Danaher by 0.5% during the third quarter. Prime Capital Investment Advisors LLC now owns 9,203 shares of the conglomerate’s stock valued at $2,039,000 after acquiring an additional 45 shares during the last quarter. Essential Investment Partners LLC boosted its stake in shares of Danaher by 34.6% in the third quarter. Essential Investment Partners LLC now owns 175 shares of the conglomerate’s stock worth $39,000 after acquiring an additional 45 shares during the last quarter. Veery Capital LLC boosted its stake in shares of Danaher by 3.1% in the third quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock worth $350,000 after acquiring an additional 48 shares during the last quarter. Studio Investment Management LLC increased its position in shares of Danaher by 3.3% during the second quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock worth $302,000 after purchasing an additional 51 shares in the last quarter. Finally, Meridian Financial Partners LLC increased its position in shares of Danaher by 1.2% during the third quarter. Meridian Financial Partners LLC now owns 4,636 shares of the conglomerate’s stock worth $1,073,000 after purchasing an additional 56 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.